Trial Profile
Phase II Double-Blind Placebo-Controlled Trial of CY503 in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Aviscumine (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 04 Mar 2011 Planned end date changed from 1 Nov 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.
- 15 Jul 2009 New trial record